New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

Sleep's role to down-scale glutamate, excitatory, frontal cortical synapses is extended to include an up-scaling of metaplastic LTP potential, in recovery from prolonged waking induced saturation of ...

Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, Our NDA filing is the culmination of over 8 years of clinical research a ...

A groundbreaking study suggests that IBS might be more of a brain issue than a gut disorder. Researchers found that ...

Dr. Raheja has expanded psychiatric care through telepsychiatry, bringing services to rural Wisconsin at Thedacare Regional ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

Irritable bowel syndrome (IBS) is a common digestive disorder that affects the intestine, causing symptoms such as abdominal pain, bloating, gas, and changes in bowel habits, including diarrhea, ...

Irritable bowel syndrome (IBS) is a common digestive disorder that affects the intestine, causing symptoms such as abdominal pain, bloating, gas, and ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

Scientists have pinpointed a brain circuit that, when activated, reduces anxiety without impairing memory. Using ...

Dissociation is the brain’s defense against overwhelming stress, involving altered brain regions, neurotransmitters, and ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.